Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma
Status:
Recruiting
Trial end date:
2024-01-05
Target enrollment:
Participant gender:
Summary
This is an open-label, phase II study evaluating efficacy and safety of Nab-paclitaxel
Combined With Bevacizumab for unresectable Recurrent or metastatic neuroendocrine carcinoma.